Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.37 HKD
−282.62 M HKD
5.21 B HKD
242.85 M
About SIPAI HEALTH TECHNOLOGY CO LTD
Sector
Industry
CEO
Xu Guang Ma
Website
Headquarters
Shanghai
Founded
2014
FIGI
BBG01BYBJ751
Sipai Health Technology Co., Ltd. is a medical technology and health management company. It operates through the following segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business. The Specialty Pharmacy Business segment includes drug-related solutions for patients, doctors, companies and insurance based on drug supply and pharmacy care services. The Physician Research Assistance Business segment focuses on the clinical trial site management services for oncology clinical trials to assist researchers and research institutions in the field of oncology to conduct clinical trials. The Health Insurance Services Business segment refers to the customized health, medical, and insurance professional services for urban population and corporate clients. The company was founded by Xu Guang Ma and Ji Li in 2014 and is headquartered in Shanghai, China.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 314 is 5.38 HKD — it has decreased by −0.55% in the past 24 hours. Watch SIPAI HEALTH TECHNOLOGY CO LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange SIPAI HEALTH TECHNOLOGY CO LTD stocks are traded under the ticker 314.
314 stock has risen by 6.32% compared to the previous week, the month change is a −8.50% fall, over the last year SIPAI HEALTH TECHNOLOGY CO LTD has showed a −22.37% decrease.
314 stock is 5.26% volatile and has beta coefficient of 0.30. Track SIPAI HEALTH TECHNOLOGY CO LTD stock price on the chart and check out the list of the most volatile stocks — is SIPAI HEALTH TECHNOLOGY CO LTD there?
Today SIPAI HEALTH TECHNOLOGY CO LTD has the market capitalization of 4.11 B, it has increased by 6.71% over the last week.
Yes, you can track SIPAI HEALTH TECHNOLOGY CO LTD financials in yearly and quarterly reports right on TradingView.
SIPAI HEALTH TECHNOLOGY CO LTD is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
314 net income for the last half-year is −84.74 M HKD, while the previous report showed −176.58 M HKD of net income which accounts for 52.01% change. Track more SIPAI HEALTH TECHNOLOGY CO LTD financial stats to get the full picture.
No, 314 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 3.10 K employees. See our rating of the largest employees — is SIPAI HEALTH TECHNOLOGY CO LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SIPAI HEALTH TECHNOLOGY CO LTD EBITDA is −200.57 M HKD, and current EBITDA margin is −4.89%. See more stats in SIPAI HEALTH TECHNOLOGY CO LTD financial statements.
Like other stocks, 314 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SIPAI HEALTH TECHNOLOGY CO LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SIPAI HEALTH TECHNOLOGY CO LTD technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SIPAI HEALTH TECHNOLOGY CO LTD stock shows the sell signal. See more of SIPAI HEALTH TECHNOLOGY CO LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.